Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy. Hindie E. Lancet Oncol 2023;24:e356.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hindie E. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy. Lancet Oncol 2023;24:e356.
PMID: 37657471